Multiple attack study on the available triptans in Italy versus placebo

European Journal of Neurology

Volumn 12, Issue 7, 2005, Pages 557-563

  Vollono, C ^a   Capuano, A ^a   Mei, D ^a,c   Ferraro, D ^a   Pierguidi, L ^b   Evangelista, M ^a   Di Trapani, Girolamo ^a,d  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Italian Hospital Group   (Italy)

^d FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Almotriptan; Eletriptan; Migraine; Multiple attack; Rizatriptan; Sumatriptan; Triptans; Zolmitriptan

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ADULT; AGITATION; ANALGESIA; ANXIETY DISORDER; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERESTHESIA; ITALY; MALE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NIGHTMARE; PARESTHESIA; PRIORITY JOURNAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; STATISTICAL ANALYSIS; THORAX PAIN; VERTIGO;

ADULT; FEMALE; HUMANS; INDOLES; ITALY; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLIDINONES; PYRROLIDINES; SEROTONIN AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME; TRIAZOLES; TRYPTAMINES;

EID: 21844461613     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2005.01030.x     Document Type: Article

References (55)

1. Adelman JU, Lipton RB, Ferrari MD et al. (2001). Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology 57:1377-1383.
2. Aurora SK, Welch KM (2000). Migraine: imaging the aura. Curr Opin Neurol 13:273-276 (Review).
3. Brown EG, Endersby CA, Smith RN, Talbot JC (1991). The safety and tolerability of sumatriptan: an overview. Eur Neurol 31:339-344.
4. Dahlof CGH, Lipton RB, McCarroll KA, Kramer MS, Lines CR, Ferrari MD (2000). Within-patient consistency of response of rizatriptan for treating migraine. Neurology 55:1511-1516.
5. Dahlof C, Fabri M, Loftus J, Jones M, Mansbach H, Scott A (2001). Triptan efficacy and preference: results of a randomized, multi-centre, open-label, crossover study of sumatriptan, naratriptan, rizatriptan, and zolmitriptan tablets in acute treatment of migraine. Cephalalgia 21: 410.
6. Dahlof CGH, Dodick D, Dowson AJ, Pascual J (2002). How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. Headache 42:99-113.
7. Davies GM, Santanello NC, Lipton RB (2000). Determinants of patient satisfaction with migraine therapy. Cephalalgia 20:554-560.
8. Diener H-C, Dowson AJ, Ferrari M, Nappi G, Tfelt-Hansen P (1999). The Study Group. Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials. Cephalalgia 19:699-700.
9. Ferrari MD (1998). Migraine. Lancet 351:1043-1051.
10. Ferrari MD (1999). How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence. Cephalalgia 19 (Suppl. 23):2-8.
11. Ferrari MD, James MH, Bates D, Pilgrim A, Ashford E, Anderson BA et al. (1994). Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrence. Cephalalgia 14:330-338.
12. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001). Triptans (serotonin, 5-HT1B/1D agonists) in acute migraine treatment - a meta-analysis of 53 trials. Lancet 358:1668-1675.
13. Ferrari MD, Goadsby PJ, Roon KI & Lipton RB (2002). Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22:633-658.
14. Goadsby PJ (2000). The pharmacology of headache. Prog Neurobiol 62:509-525.
15. Goadsby PJ (2001). The pathophysiology of headache. In: Silberstein SD, Lipton RB, Solomon S, eds. Wolff's Headache and Other Head Pain, 7th edn. Oxford University Press, Oxford, pp. 57-67.
16. Goadsby PJ, Edvinsson L (1994). Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5-HT)-1D receptor agonist 311C90. Headache 34:394-399.
17. Goadsby PJ, Hoskin KL (1996). Inhibition of trigeminal neurones by intravenous administration of the serotonin (5HT)1B/D agonist zolmitriptan (311C90): are brain stem sites therapeutic targets in migraine? Pain 67: 355-359.
18. Goadsby PJ, Hoskin KL (1998). Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5HT1B/1D receptor: a central action in migraine? Ann Neural 43:711-718.
19. Goadsby PJ, Knight YE (1997). Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia 17:153-158.
20. Goadsby PJ, Edvinsson L, Ekman R (1988). Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann Neural 23:193-196.
21. Goadsby PJ, Ferrari MD, Olesen J et al. (2000a). Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 54:156-163.
22. Goadsby PJ, Ferrari MD, Stovner LJ, Senard JM, Jackson NC, Poole PH (2000b). Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan - reply. Neurology 55:736.
23. Goadsby PJ, Lipton RB, Ferrari MD (2002). Migraine: current understanding and management. N Engl J Med 346:257-270.
24. Goldstein J, Ryan R, Jiang K et al. (1998). Crossover comparison of rizatriptan 5 mg and 10 mg vs sumatriptan 25 mg and 50 mg in migraine. Headache 38:737-747.
25. Goldstein DJ, Offen WW, Lipton RB (1999). Effect of different endpoints on placebo response in acute migraine. Cephalalgia 19:366.
26. Gruffyd-Jones K, Kies B, Middleton A, Mulder LJMM, Røsjø Ø, Millson DS (2001). Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double blind, international study. Eur J Neurol 8:237-245.
27. Humphrey PPA, Feniuk W, Perren MJ, Beresford IJM, Skingle M, Whalley ET (1990). Serotonin and migraine. Ann NY Acad Sci 600:587-598.
28. International Headache Society Committee on Clinical Trials in Migraine (1991). Guidelines for controlled trials of drugs in migraine (1st edn). Cephalalgia 11:1-12.
29. International Headache Society Committee on Headache Classification (1988). Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 8 (Suppl. 7):1-96.
30. International Headache Society Subcommittee on Clinical Trials (2000). Guidelines for controlled trials of drugs in migraine (2nd edn). Cephalalgia 20:765-786.
31. Kramer MS, Matzura-Wolfe D, Polis A, Getson A, Amaraneni PG, Solbach MP et al. (1998). A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology 51:773-781.
32. Lambert GA, Michalicek J, Storer RJ, Zagami AS (1999). Effect of cortical spreading depression on activity of trigeminovascular sensory neurons. Cephalalgia 19:631-638.
33. Lee Y, Conroy A, Stepanavage ME, Mendel CM, Somers G, McLoughlin DA (1999). Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. Br J Clin Pharmacol 43:49-54.
34. Linde M, May A, Limmroth V, Dahlof C (2003). Headache Masters Programme. Ethical aspects of placebo in migraine research. Cephalalgia 23:491-495.
35. Lines C, Visser WH, Vandormael K, Reines SA (1997). Rizatriptan 5 mg versus sumatriptan 50 mg in the acute treatment of migraine. Headache 37:319-320.
36. Lipton RB, Stewart WF (1999). Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 39 (Suppl. 2):S20-S26.
37. Maassen Van Den Brink A, Reekers M, Bax WA, Ferrari MD, Saxena PR (1998). Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98:25-30.
38. Mathew NT, Kailasam J, Gentry P, Chernyshev O (2000). Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial. Headache 40:464-465.
39. Moskowitz MA (1984). The neurobiology of vascular head pain. Ann Neurol 16:157-168.
40. Moskowitz MA (1992). Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 14:401-410.
41. Ottervanger JP, Valkenburg HA, Grobbee DE, Stricker BHC (1997). Characteristics and determinants of sumatriptan-associated chest pain. Arch Neural 54:1387-1392.
42. Pascual J, Vega P, Diener H-C, Allen C, Vrijens F, Patel K and the Rizatriptan-Zolmitriptan Study Group (2000). Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia 20: 455-461.
43. Pascual J, Munõz R, Leira R (2001). An open preference study with sumatriptan 50 mg and zolmitriptan 2.5 mg in 100 migraine patients. Cephalalgia 21:680-684.
44. Pini LA, Sternieri E, Fabbri L, Zerbini O, Bamfi F (1995). The Oral Sumatriptan Italian Study Group. High efficacy and low frequency of headache recurrence after oral Sumatriptan. J Int Med Res 23:96-105.
45. Pitman V, Forster E, Jackson NJ (1999). Comparison of the efficacy of oral eletriptan and oral sumatriptan for the acute treatment of migraine: combined analysis across three clinical trials. Headache 39:A374.
46. Rasmussen BK (1995). Epidemiology of headache. Cephalalgia 15:45-68.
47. Rasmussen BK, Jensen R, Schroll M et al. (1991). Epidemiology of headache in the general population: a prevalence study. J Clin Epidemiol 44:1147-1157.
48. Sanchez del Rio M, Reuter U, Moskowitz MA (2000). Central and peripheral mechanisms of migraine. Funct Neurol 15 (Suppl. 3): 157-162 (Review).
49. Seaber E, On N, Phillips S, Churchus R, Posner J, Rolan P (1996). The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. Br J Clin Pharmacol 41:141-147.
50. Solomon GD, Cady RK, Klapper JA, Earl NL, Saper JR, Ramadan NM (1997). Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology 49:1219-1225.
51. Stewart WF, Lipton RB, Celentano DD, Reed ML (1992). Prevalence of migraine headache in the United States. Relation to age, income, race and other sociodemographic factors. JAMA 267:64-69.
52. Stewart WF, Shechter A, Rasmussen BK (1994). Migraine prevalence. A review of population-based studies. Neurology 44 (Suppl. 4):S17-S23.
53. Tepper SJ, Rapoport AM, Sheftell FD (2002). Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 59:1084-1088 (Review).
54. Tfelt-Hansen P, Teall J, Rodriguez F et al. (1998). Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 38:748-755.
55. Welch KM (2003). Contemporary concepts of migraine pathogenesis. Neurology 61 (Suppl. 4):S2-S8 (Review).